SPONSORS
Chiesi Global Rare Diseases is a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases. As a family business, Chiesi Group strives to create a world where it is common to have a therapy for all diseases and acts as a force for good, for society and the planet. The goal of the Global Rare Diseases unit is to ensure equal access so as many people as possible can experience their most fulfilling life. The unit collaborates with the rare disease community around the globe to bring voice to underserved people in the health care system. For more information visit www.chiesirarediseases.com.
Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company with a heritage of 70+ years, we apply cutting-edge science including an expertise in antibody research and engineering, to address the needs of patients and society across multiple therapeutic areas including Nephrology, Oncology, Immunology/Allergy and Neurology. Across four regions – Japan, Asia Pacific, North America and EMEA/International – we focus on our purpose, to make people smile, and are united by our shared values of commitment to life, teamwork/Wa*, innovation and integrity.
You can learn more about the business of Kyowa Kirin at:
https://international.kyowa-kirin.com/
*Harmony and loop among people.
Chemo is part of the Spanish multinational Insud Pharma, a group with more than 45 years of history and 9000 professionals worldwide. Insud Pharma has a presence in all links of the chemical-pharmaceutical industry thanks to three synergistic business units: industrial (Chemo), brand (Exeltis) and biotechnology (mAbxience). Our goal is to preserve and improve people’s health and well-being.
Chemo is a benchmark for the industry in research, development and manufacturing of a wide variety of active pharmaceutical ingredients (APIs) and a complete range of finished dosage forms (FDFs), both for human and veterinary use, for the main therapeutic areas.
We work to provide our partners with generic drugs of the highest standard, manufactured and packaged in our European facilities. We go hand in hand throughout the process, providing support in all aspects related to the complete product cycle (pharmaceutical development, registration, intellectual property, launch and logistical organization). Our spirit of customer service enables us to ensure strong relationships with our partners around the world. Service, innovation and quality make Chemo one of the most reliable generic suppliers in the B2B business.
State-of-the-art technology, high industrial capacity and vertical integration with our API plants mean that we control the processes from start to finish, making us a trusted partner for more than 1100 pharmaceutical companies in 96 countries.
Inmunova is an Argentine biotech company dedicated to researching and developing innovative medicines for rare infectious diseases lacking treatment options.
Our expertise lies in designing vaccines, therapeutic antibodies, and immunogens, encompassing the entire development process: from original concept and proof-of-concept studies to preclinical and clinical phases, registration procedures, and pharmacovigilance.
We are part of Insud, a globally diversified company operating in over 40 countries, with a significant presence in the pharmaceutical industry.
Currently, we are entering the final stage of research for the world’s first treatment for hemolytic uremic syndrome (HUS). The clinical development programme has been endorsed by the Food and Drug Administration (FDA), and the European Medicines Agency (EMA), receiving Orphan Drug designation in both Europe and the United States, as well as Rare Pediatric Disease Designation in the US.
At Inmunova, our priority is to generate treatment options using high global standards of quality and best practices for product research and development. Innovation and scientific solidity are the cornerstones of our work.
At Recordati Rare Diseases, we focus on the few – those affected by rare diseases. We believe that every single patient has the right to the best possible treatment. Patients with rare diseases are our top priority. They are at the core of our planning, our thinking and our actions.
Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases. As a leader in rare diseases for nearly 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines.
Bayer is an innovation leader in the area of cardiovascular diseases, with a long-standing commitment to delivering science for a better life by advancing a portfolio of innovative treatments. The heart and the kidneys are closely linked in health and disease, and Bayer is working in a wide range of therapeutic areas on new treatment approaches for cardiovascular and kidney diseases with high unmet medical needs. The cardiology franchise at Bayer already includes a number of products and several other compounds in various stages of preclinical and clinical development. Together, these products reflect the company’s approach to research, which prioritizes targets and pathways with the potential to impact the way that cardiovascular diseases are treated.
For more information, go to www.bayer.com.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our Rare Disease division is the speciality care unit of Novo Nordisk focused on generating scientific and technological breakthroughs for people living with a rare disease by discovering and developing integrated therapeutic solutions and novel indications of established medicines in rare blood and endocrine disorders. Novo Nordisk employs about 77,000 people in 80 countries, of which around 4,000 work with rare diseases.
Advicenne is dedicated to developing innovative, effective and safe treatments for people living with rare renal diseases who have very limited therapeutic options. Thanks to our expertise in reformulation and drug delivery, we are uniquely positioned to develop and make available innovative treatments for both children and adults.
We are dedicated to improving patients’ daily health and life and are committed to tackle the challenge of high unmet medical needs.
Sibnayal® (combination of Potassium citrate and Potassium bicarbonate) has received its Marketing Approval for distal renal tubular acidosis (dRTA) in EU and GB. Sibnayal® is approved for both the genetic and acquired form of dRTA. For more information, visit www.advicenne.com.
Avanzanite Bioscience is a commercial-stage specialty pharmaceutical company, whose sole mission is to ensure novel medicines reach patients suffering from rare diseases in every market across Europe.
Derived from the word “Tanzanite” – one of the rarest and most underappreciated gemstones on earth – Avanzanite was formed to capitalize on two primary objectives, one economic, and one humanitarian.
The economic goal is to enter commercial and/or development partnerships with research-based biopharmaceutical originators to unlock the full value of their orphan medicines in European markets and beyond; this is a unique expertise and core competency of the experienced Avanzanite team through its decades of navigating this area.
Many of these biotechs develop breakthrough Orphan Drugs, however they often do not reach patients in need which is a shame and unfair.
Equally important, the Company’s humanitarian goal stems from our commitment to enabling access mostly to novel or even already commercialised medicines, for patients who suffer from orphan diseases, regardless of where they live in Europe.
Avanzanite acquires, licenses or distributes approved or late-stage medicines for rare diseases and commercialises them everywhere in Europe (and beyond), even when nobody else will.
Avanzanite’s founding mission is to tackle these critical issues in the European orphan drug space and beyond, with our unique business model since we believe patients with Rare Diseases should have access to the latest medical innovations regardless of where they live.
BioPorto’s NGAL tests aid in the rapid risk assessment of acute kidney injury (AKI), providing clinicians with an additional data point to confidently initiate interventions earlier. A low NGAL value indicates a low risk of AKI, allowing for confident use of interventions such as fluids, diuretics, or nephrotoxic medications. Elevated NGAL values signal a high risk of developing AKI and can trigger nephrology consultations and interventions 2-3 days before serum creatinine rises.
Meet the Experts – Stand 26 | Friday, October 17th | 10:30-11:00
Join us in the exhibit hall as three NGAL experts from two continents share their experience using an NGAL result to improve AKI management in their patients.
Learn more about AKI, the NGAL biomarker, and The NGAL Test at www.bioporto.com
Fresenius Medical Care is the world’s leading provider of products and services for people with kidney diseases, of whom approximately 4.1 million patients worldwide receive regular dialysis treatment. Through its network of 3,862 dialysis centers, Fresenius Medical Care provides dialysis treatment for approximately 325,000 patients worldwide and is the leading provider of dialysis products such as dialysis machines and dialyzers.
Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. Inozyme is developing INZ-701, an enzyme replacement therapy, to address pathologic mineralization and intimal proliferation, which can drive morbidity and mortality in these severe diseases. INZ-701 is currently in clinical development for the treatment of ENPP1 Deficiency, ABCC6 Deficiency and calciphylaxis.
Food for Special Medical Purposes: Made in Germany – Available Worldwide
metaX, founded in 1999, is an independent German family business. We work with prestigious universities and special hospitals, research laboratories, and competent business partners in Germany and worldwide. We are a team of highly motivated professionals dedicated to working creatively on innovations in nephrological and metabolic dietetics. metaX offers dietetic Food for Special Medical Purposes: Products for the dietetic management of Chronic Renal Failure, Protein Supplements for inborn errors of metabolism, a wide range of Low Protein Products, Supplements for Food Fortification, and Micronutrient Supplements.
Certified Quality – Service to Our Customers
metaX develops and manufactures almost all their products themselves. metaX is a company certified according to HACCP and ISO 9001:2015. State-controlled production facilities, many years of experience, sound knowledge, and highest quality demands provide excellent product quality. Our products are analyzed and monitored by accredited laboratories – service to our customers, without compromise.
metaX services include brochures, recipes, cooking classes, patient holiday activities, and medical symposia for professionals.
Dedicated to the Health and Wellbeing of People
At metaX, we are unwaveringly dedicated to the health and wellbeing of people. This commitment is at the core of everything we do. The symbol “X” in the metaX company logo represents a human being. It symbolizes that metaX is dedicated to the well-being and health of people. The personal interaction with the people for whom our products are developed is very close to our hearts. We look forward to hearing from you!
At Mozarc Medical, we use technology and expertise to change the treatment of kidney disease. Empowering providers with a holistic, comprehensive portfolio. Providing caregivers with unwavering support. And always putting the patient first.
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.
Vitaflo™ International Ltd are at the forefront of developing specialised clinical nutrition products for Inborn Errors of Metabolism (IEM), disease related malnutrition, drug resistant epilepsy (DRE) and disease specific conditions such as paediatric kidney disease.
Our approach has always been to create products that combine the best of cutting edge research with the lifestyle demands of modern living to produce products that are both innovative and well accepted by patients. We have two products specifically developed for children with kidney disease; Renastart™ and Renastep™ as well as a host of resources for both Healthcare Professionals and patients to aid education regarding the dietary management of paediatric kidney disease.
Come and visit our stand to find out more about our products, resources and educational initiatives for Healthcare Professionals.
Immundiagnostik AG is an internationally active diagnostics company developing and manufacturing innovative immunoassays and other analytical methods for routine and research. Immundiagnostik provides novel immunoassays and analytical tools focused on gastroenterology, nutrition, cardiovascular and renal diseases, bone metabolism, clinical immunology, oncology and more. We also offer laboratory support services, including proficiency testing, custom bulk packaging, and validation assistance. Visit Immundiagnostik to discover more about our products, services, and brands.
EXHIBITION
An exhibition of the latest pharmaceutical products, electro-medical devices and scientific publications is planned during the ESPN annual meeting. There will be ample opportunity to visit the Technical Exhibition and to liaise with the representatives of the sponsoring companies.
For more information on Sponsors & Exhibitors opportunity, please contact Sponsor& Exhibitor Department sponsorespn@oic.it.
OIC Srl
Viale Giovine Italia, 17
50122 Florence – Italy
Tel. +39 055 5035359
E-mail sponsorESPN@oic.it